CAJ | 학술논문

【目的】研究miR‐28‐5p在弥漫大B细胞淋巴瘤（DLBCL ）中的表达，探讨miR‐28‐p表达与DL‐BC L临床病理特征的关系。【方法】采用免疫组织化学S P法对本科2007年2月至2014年10月有详细随访资料的41例DLBCL进行急性淋巴母细胞性白血病抗原（CD10）、bcl‐6、多发性骨髓瘤致癌基因（Mum‐1）免疫标记，同时采用实时荧光定量聚合酶链反应（RT‐PCR）方法检测其miR‐28‐P的表达水平，以12例淋巴结反应性增生作为对照组。【结果】miR‐28‐5p在DLBCL中表达水平低于对照组（ P ＝0．000），且在GCB亚型中表达高于non‐GCB亚型（ P ＝0．011）。miR‐28‐5p在DLBCL中的表达与国际预后指数（IPI）呈正相关，与年龄、性别、Ann Arbor分期和血清LDH水平无关。【结论】miR‐28‐5p在DLBCL中表达降低，并与其免疫分型密切相关，对预后可能有一定的指导意义，可作为DLBCL诊疗的潜在标志物之一，值得临床进一步研究。
【목적】연구miR‐28‐5p재미만대B세포림파류（DLBCL ）중적표체，탐토miR‐28‐p표체여DL‐BC L림상병리특정적관계。【방법】채용면역조직화학S P법대본과2007년2월지2014년10월유상세수방자료적41례DLBCL진행급성림파모세포성백혈병항원（CD10）、bcl‐6、다발성골수류치암기인（Mum‐1）면역표기，동시채용실시형광정량취합매련반응（RT‐PCR）방법검측기miR‐28‐P적표체수평，이12례림파결반응성증생작위대조조。【결과】miR‐28‐5p재DLBCL중표체수평저우대조조（ P ＝0．000），차재GCB아형중표체고우non‐GCB아형（ P ＝0．011）。miR‐28‐5p재DLBCL중적표체여국제예후지수（IPI）정정상관，여년령、성별、Ann Arbor분기화혈청LDH수평무관。【결론】miR‐28‐5p재DLBCL중표체강저，병여기면역분형밀절상관，대예후가능유일정적지도의의，가작위DLBCL진료적잠재표지물지일，치득림상진일보연구。
[Objective] To explore the expression of miR‐28‐5p in diffuse large B‐cell lymphoma (DLBCL ) and its relationship with clinicopathological features .[Methods] Immunohistochemistry was used for CD10 ,bcl‐6 and Mum‐1 in 41 DLBCL patients with follow‐up data .The expression level of miR‐28‐5p was examined by TaqMan real‐time polymerase chain reaction (RT‐PCR) .And 12 cases of reactive lymph node were selected as control .[Results]The expression of miR‐28‐5p was significantly lower in DLBCL group than that in control group( P=0 .000)and it was significantly higher in GCB group than non‐GCB group( P=0 .000) .And correlated with international prognos‐tic index (IPI) ,miR‐28‐5p was higher in (0~2) group than that in (3~5) group( P=0 .11) .There was no rela‐tionship of miR‐28‐5p expression with other clinicopathological features ( P >0 .05) .[Conclusion] A down‐regula‐tion of miR‐28‐5p is correlated with immunophenotypes in DLBCL .And miR‐28‐5p may have some guiding signifi‐cance in prognosis and it is a potentially useful diagnostic marker .